EMD Serono, Inc.
- Given via intravenous infusion, the dose varies according to an individual's weight. It is administered once every three months for a maximum of two-to-three years. The total dose that can be taken is limited to avoid the risk of damage to the heart. Careful monitoring both during and after treatment is necessary.
- Novantrone is approved for use in SPMS, progressive-relapsing MS (PRMS), worsening RRMS, and people who are not responding favorably to standard therapies.
- This drug appears to delay the time to a first-treated relapse, reduces the number of relapses, delays the time to disability progression, and decreases the number of new lesions that can be detected by MRI. It also appears to stabilize disease activity in some individuals with SPMS.
- Novantrone is an immunosuppressant that has been used for years to treat cancer. It targets rapidly dividing cells, including those believed to be involved in MS. Side effects may include cardiac disease and leukemia; patients must be closely monitored to minimize these risks. Chemotherapy-induced amenorrhea (cessation of periods) was seen in about one-fourth of treated women. Use in the United States is declining due to these side effects.